A Phase 2 Interventional, Multicenter, Randomized Open Label Study to Determine the Effective and Tolerable Dose of KAF156 and Lumefantrine Solid Dispersion Formulation in Combination, Given Once Daily for 1, 2 and 3-days to Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Ganaplacide (Primary) ; Artemether/lumefantrine; Lumefantrine
- Indications Falciparum malaria
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 05 Jun 2019 Planned End Date changed from 19 Jun 2020 to 22 Sep 2020.
- 29 May 2019 Planned End Date changed from 10 Jan 2020 to 19 Jun 2020.
- 08 Feb 2019 Planned End Date changed from 25 Oct 2019 to 10 Jan 2020.